Mubucho (Dasatinib)

Dasatinib, the active ingredient in Mubucho, is a tyrosine kinase inhibitor presented as an oral tablet for oral use and is marketed in the European Union. It is indicated for the treatment of chronic myeloid leukemia and Philadelphia chromosome‑positive acute lymphoblastic leukemia in adult patients.

GNH USA supplies Mubucho as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Dasatinib is a tyrosine kinase inhibitor used in hematologic malignancies that involve BCR‑ABL signaling. - Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and achieves hematologic and cytogenetic responses. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): induces remission and improves overall survival. - Imatinib‑resistant CML: provides an alternative therapeutic option when first‑line tyrosine kinase inhibition fails.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: watery stools, often self‑limiting. - Fatigue: generalized tiredness. - Rash: skin erythema or pruritus. - Headache: transient cranial discomfort. - Myelosuppression: reduced blood cell counts.

Serious or Rare Side Effects: - Pleural effusion: accumulation of fluid around the lungs. - Pulmonary hypertension: elevated pressure in pulmonary arteries. - Severe hemorrhage: uncontrolled bleeding events. - Cardiac dysfunction: reduced left‑ventricular ejection fraction. - Severe infections: opportunistic bacterial or fungal infections. - Hepatotoxicity: significant liver enzyme elevation.

Patients should be monitored for safety concerns before and during therapy. - Blood count monitoring: perform complete blood counts regularly to detect myelosuppression. - Liver function assessment: evaluate hepatic enzymes prior to initiation and periodically thereafter. - Cardiac evaluation: assess for signs of pulmonary hypertension or heart failure. - Avoid strong CYP3A4 inhibitors: concomitant use may increase dasatinib exposure. - Caution in bleeding disorders: assess risk before prescribing. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Dasatinib may interact with other medicines that affect its metabolism or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can markedly increase dasatinib plasma levels. - Antifungal azoles (e.g., voriconazole): potentiate exposure and toxicity. - Potent enzyme inducers (e.g., carbamazepine, phenytoin): may reduce therapeutic effect.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may modestly affect absorption. - Anticoagulants (e.g., warfarin): increase risk of bleeding; monitor coagulation parameters.